• Clear commitment to Switzerland as a location for research and production
• Investments in another research building, renewal of chemical production and the Institute of Human Biology
• Modernisation of research and production infrastructure
  
  

Basel, 17 November 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans to further renew its infrastructure at the Basel site. Over the next few years, Roche will invest CHF 1.2 billion in another research and development building, the renewal of the synthetic chemical molecule production and a building for the Institute of Human Biology. CHF 3 billion have been invested in the site since 2014.

Jürg Erismann, Head of the Basel/Kaiseraugst Site, comments: “The investment of another CHF 1.2 billion is an important step for the future of the Basel site. The new buildings will expand the infrastructure for future innovations along the entire pharmaceutical value chain, from research to production. This is another clear commitment to the Basel research and production site and to Switzerland.”

The planned investments of CHF 1.2 billion include the following projects:

Building 12 / research and development building

• To serve as an important link between research and development departments in the global Roche network
• 72 metres high with 13 storeys
• State of art laboratory workstations for up to 450 researchers
• Total investment of around CHF 500 million

Building 50 and 51 / synthetic and chemical production

• New production building for manufacturing synthetic medicines. This is an area in which Roche has a broad pipeline of new active substances
• Replacement of existing site infrastructure with new Building 51 and refurbishment and expansion of existing Building 50
• Total investment of around CHF 570 million

Building 92 / Institute of Human Biology

• Development of innovative organoids to improve the understanding of diseases and develop treatments
• Space for up to 250 researchers of the Institute of Human Biology
• The existing Building 92 will be completely rebuilt to adapt it to the needs of the institute
• The building is also home to central laboratory services for research
• Total investment of around CHF 100 million

The planned development will be realised within the framework of the existing building plan for the northern part of the site. We expect the construction of the research building and the building renovations to be completed by 2030.

Renderings, facts and figures and a film about site development are available at www.roche.ch  

You can find more information about the Institute of Human Biology here.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Global Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Attachment

• 17112023_MR_Arealentwicklung_2023_en